Sunday, December 21, 2014

Deals

ONO and Gilead Announce Exclusive License Agreement

December 21, 2014 · Leave a Comment 

  OSAKA, Japan & FOSTER CITY, Calif.–(BUSINESS WIRE)– ONO PHARMACEUTICAL CO., LTD. (“ONO”) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO’s oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies... [Read the full story]

Deal News

ONO and Gilead Announce Exclusive License Agreement

December 21, 2014 · Leave a Comment 

  OSAKA, Japan & FOSTER CITY, Calif.–(BUSINESS WIRE)– ONO PHARMACEUTICAL CO., LTD. (“ONO”) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO’s oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies... [Read the full story]

Legal

Philips, Nintendo Resolve Patent Disputes; Reaches Patent License Agreement

December 2, 2014 · Leave a Comment 

  Koninklijke Philips Electronics NV (PHGFF.PK,PHG: Quote) said it has resolved the patent disputes and also reached a patent license agreement with Nintendo Co. Ltd. (NTDOY.PK). Therefore, the patent infringement proceedings that Philips had initiated in Germany, the UK, France and the USA against Nintendo’s Wii, Wii U and DS handheld products would end. Pursuant to the agreement, both the firms would cross-license portions of each company’s patent portfolio. The terms and financial details of the license deal are not disclosed. “We are very pleased to have reached this... [Read the full story]

Bio

Bioject and Immunomic Therapeutics Enter into an Agreement

December 21, 2014 · Leave a Comment 

  Tigard, OR and Hershey, PA (PRWEB) December 19, 2014 Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into an agreement with Immunomic Therapeutics, Inc. (ITI) for ITI to use the Biojects Biojector®-2000 needle-free injection device with its LAMP vaccine platform. In the agreement, ITI receives an option for an exclusive Worldwide license to the Biojector®-2000 that triggers based on the achievement of certain clinical milestones. The agreement contains provisions for development... [Read the full story]

University Tech Transfer

RedHill Biopharma Acquires Technology from University of Minnesota

December 18, 2014 · Leave a Comment 

  TEL-AVIV, Israel, Dec. 18, 2014 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (“RedHill” or “Company”), an Israeli biopharmaceutical company primarily focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it has entered into a license agreement with the University of Minnesota to acquire the rights to a patented technology to support the development of a commercial diagnostic test for detection of Mycobacterium avium subspecies paratuberculosis (“MAP”)... [Read the full story]

People

Boulder’s Innovation Center of the Rockies signs commercialization agreement with University of Wyoming

October 11, 2013 · Leave a Comment 

  The Innovation Center of the Rockies, a Boulder-based organization created to help research institutions commercialize technology, has entered into an agreement with the University of Wyoming, officials announced Tuesday. Financial terms of the agreement were not disclosed. The University of Wyoming is the first commercialization partner outside the state of Colorado for the nonprofit Innovation Center of the Rockies, which has inked similar deals with the University of Colorado, Colorado School of Mines, Colorado State University and the University of Denver. “I think that we’ve... [Read the full story]

Deals

ONO and Gilead Announce Exclusive License Agreement

  OSAKA, Japan & FOSTER CITY, Calif.–(BUSINESS WIRE)– ONO PHARMACEUTICAL CO., LTD. (“ONO”) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO’s oral Bruton’s tyrosine kinase (BTK) inhibitor... Read more of this article


Neste Oil and Renewable Energy Group Enter into NEXBTL License Agreement

  Neste Oil Corporation of Finland and Renewable Energy Group, Inc. (NASDAQ: REGI), headquartered in Ames, Iowa, USA have entered into a Settlement and License Agreement whereby the parties have settled Neste Oil’s US patent infringement lawsuits against REG and REG’s Singapore patent infringement lawsuits against Neste Oil and REG... Read more of this article


Bioject and Immunomic Therapeutics Enter into an Agreement

  Tigard, OR and Hershey, PA (PRWEB) December 19, 2014 Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into an agreement with Immunomic Therapeutics, Inc. (ITI) for ITI to use the Biojects Biojector®-2000 needle-free injection device... Read more of this article


Cardiome Enters Development And Commercialization Agreement With Eddingpharm

  Vancouver, Canada, Dec 19, 2014 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that one of its subsidiaries has entered into an agreement with Eddingpharm to develop and commercialize BRINAVESS™ in China, Taiwan, and Macau and re-launch BRINAVESS in Hong Kong. Eddingpharm will be responsible for any clinical trials... Read more of this article


BioLineRx, Novartis to develop and commercialize Israeli-sourced drug candidates

  Clinical-stage biopharmaceutical company BioLineRx and Novartis Pharma have reached a multi-year strategic collaboration agreement to support the development and commercialization of Israeli-sourced drug candidates. As part of the partnership, both the firms will jointly evaluate both clinical and pre-clinical stage projects that will be identified... Read more of this article


Chimerix (CMRX), ContraVir Pharma Enter Strategic Collaboration

  DURHAM, N.C. and EDISON, N.J., Dec. 18, 2014 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX) a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral... Read more of this article


ObjectVideo Patent Licensing Program Acquired By Avigilon For A Cash Consideration Of $80.3M

  Reston, Va., USA (December 18, 2014) – ObjectVideo, Inc., a technology and solutions company, and Avigilon Corporation (TSX: AVO), a leading global provider of end-to-end security solutions, announced today the sale of ObjectVideo’s intellectual property and patent licensing program to Avigilon for a cash consideration of $80.3 million. “From... Read more of this article


Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement

  December 18, 2014 — New Brighton (Minnesota, USA) and Evanston (Illinois, USA) — Cellectis plant sciences, a Minnesota-based company focusing on developing healthier food products, and the Two Blades Foundation (2Blades) today announced the execution of a non-exclusive cross-license agreement relating to TAL nuclease technologies.  Read More →


RedHill Biopharma Acquires Technology from University of Minnesota

  TEL-AVIV, Israel, Dec. 18, 2014 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (“RedHill” or “Company”), an Israeli biopharmaceutical company primarily focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that... Read more of this article


Marina Biotech and MiNA Therapeutics Announce License Agreement

  Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA)... Read more of this article


More Posts From Deals

Legal

Philips, Nintendo Resolve Patent Disputes; Reaches Patent License Agreement

  Koninklijke Philips Electronics NV (PHGFF.PK,PHG: Quote) said it has resolved... 


Acacia Subsidiary Enters into Settlement and Release Agreement with Axiom Process

  NEWPORT BEACH, Calif.–(BUSINESS WIRE)– Acacia Research Corporation... 


More Posts From Legal

University Tech Transfer

RedHill Biopharma Acquires Technology from University of Minnesota

  TEL-AVIV, Israel, Dec. 18, 2014 (GLOBE NEWSWIRE) — RedHill Biopharma... 


eSurface® Technologies Signs Licensing Agreement with Utah Valley University

  CARLSBAD, Calif.–(BUSINESS WIRE)--eSurface® Technologies (DBA of EarthOne... 


More Posts From University Tech Transfer